Elanco Wins FDA Emergency Authorization for New World Screwworm Drug

The U.S. Food and Drug Administration on Thursday granted an Emergency Use Authorization (EUA) to Elanco Animal Health (ELAN) for CLiK Extra, a wound spray that prevents New World screwworm (NWS) infestations across a broad range of livestock and wildlife species. Notably, the decision hands American ranchers, veterinarians, and wildlife managers a fresh tool against a pest that threatens both farm animals and native herds — yet shares of the Indianapolis-based company fell in Thursday trading despite the regulatory win.

Key Points

• The FDA authorized CLiK Extra (dicyclanil topical suspension) wound spray specifically to prevent NWS infestations, not to treat existing ones.
• The authorization covers a wide species list, including sheep, cattle, goats, swine, and camelids, plus captive and captured wildlife such as deer, elk, American bison, bighorn sheep, and Sonoran pronghorn.
• The product works as an insect growth regulator — rather than killing larvae outright, it disrupts their development and halts their lifecycle before they damage tissue.
• CLiK Extra will sell over the counter for topical application at the time a wound appears or is created, including after procedures like dehorning, castration, tail docking, and shearing.
• The drug is not FDA-approved or conditionally approved for any indication; the EUA remains in effect only until revoked or until HHS ends the underlying emergency declaration.
• ELAN traded around $23.71, down roughly 2% on the day (previous close $24.20), even as the news broke.

What the FDA Authorized

The FDA cleared CLiK Extra for application on or around wounds, and therefore positioned it squarely as a preventive measure rather than a cure. Specifically, the agency authorized the spray to guard against screwworm myiasis tied to wounds, births, and routine surgical or husbandry procedures. Consequently, producers can apply it the moment a wound appears — but if an infestation has already taken hold, the FDA urges them to consult a veterinarian about treatment options instead.

Moreover, the agency emphasized that the drug does not simply kill NWS larvae. Instead, it functions as an insect growth regulator, which means it interrupts larval development and stops the lifecycle before the parasites can cause tissue damage in the host animal.

Why It Matters for Elanco

Because the authorization spans livestock and wildlife alike, it extends Elanco’s growing footprint in the fight against New World screwworm. FDA Center for Veterinary Medicine director Timothy Schell underscored that the threat “extends beyond the farm gate,” and he framed the inclusion of wildlife species as a way to keep animals like bighorn sheep and Sonoran pronghorn from spreading the pest across the United States. Acting FDA Commissioner Kyle Diamantas, meanwhile, cast the move as giving farmers and ranchers “the tools they need to fight back.”

Still, the market reaction stayed muted. Although the EUA broadens Elanco’s screwworm portfolio, ELAN shares slipped about 2% to roughly $23.71, leaving the company with a market capitalization near $12 billion. Even so, the timing follows an otherwise strong stretch for Elanco, which recently beat second-quarter estimates, raised its full-year 2026 outlook, and guided toward 6%–7% organic constant-currency growth with roughly 3x net leverage by year-end.

The Bottom Line

Ultimately, the EUA gives Elanco (ELAN) a timely product in a high-profile animal-health battle, and it reinforces the company’s expanding role in NWS prevention. Investors, however, appeared to shrug off the news for now — a reminder that regulatory milestones do not always move the stock in the near term.